T2 Biosystems to Report Third Quarter 2022 Financial Results on November 10, 2022
T2 Biosystems (NASDAQ:TTOO) announced it will release its third quarter 2022 financial results on November 10, 2022, after market close. A conference call will follow at 4:30 p.m. ET, which investors can access via a live and archived webcast on the company’s website. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and antibiotic resistance genes, with products like the T2Dx® Instrument and various panels powered by their proprietary T2 Magnetic Resonance (T2MR®) technology. The company aims to enhance patient care and reduce costs.
- Upcoming financial report may reveal growth in sales or new product developments.
- No specific financial metrics were provided, leaving uncertainty regarding performance.
LEXINGTON, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2022 after market close on Thursday, November 10, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section.
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Bacteria® Panel, T2Candida® Panel, T2Resistance® Panel, and T2SARS-CoV-2™ Panel and are powered by the Company’s proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat Panel, T2Cauris™ Panel, T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
When will T2 Biosystems report its third quarter 2022 financial results?
What time is the conference call for T2 Biosystems' Q3 results?
How can I listen to T2 Biosystems' Q3 earnings call?
What products does T2 Biosystems offer?
What is the significance of T2 Biosystems' proprietary technology?
